<DOC>
	<DOCNO>NCT02753686</DOCNO>
	<brief_summary>Although randomize control trial ( RCTs ) provide evidence efficacy , generalization result patient real-world set challenging , give RCTs conduct highly select patient population . An understanding effectiveness safety approve cancer therapy routine clinical practice essential order optimize management patient identify treatment safety gap . This first Canadian study describe real-world treatment patterns/sequencing , effectiveness safety postmenopausal HR+ HER2- advance breast cancer patient . This registry incorporate observational prospective cohort design enroll 320 postmenopausal HR+ HER2- advance breast cancer woman previously expose non-steroidal aromatase inhibitor ( NSAI ) therapy treat endocrine therapy ( ET ) ET combination target therapy ( TT ) .</brief_summary>
	<brief_title>Treatment Canadian Postmenopausal Women With ER+ Advanced Breast Cancer Real-World Setting With Hormone Therapy ± Targeted Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Patient inoperable locally advanced metastatic breast cancer . 2 . Patient ER positive and/or PgR positive HER2negative breast cancer local laboratory test ( base recently analyze biopsy ) . 3 . Patient postmenopausal . Postmenopausal status define either : 1 . Prior bilateral oophorectomy 2 . Or age ≥60 3 . Or age &lt; 60 amenorrhea 12 month ( absence chemotherapy , tamoxifen , toremifen , ovarian suppression ) , FSH estradiol postmenopausal range ( serum FSH &gt; 40 mIU/mL estradiol &lt; 20 pg/mL accord postmenopausal range define local laboratory ) . 4 . Patient prior exposure NSAI ( letrozole anastrozole ) therapy adjuvant metastatic setting . NSAI therapy last treatment prior study entry . Other prior anticancer therapy , e.g . tamoxifen , fulvestrant also allow . 5 . Patient receive maximum one prior chemotherapy line advanced/metastatic breast cancer allow . 6 . Patient currently receive target therapy plus endocrine therapy ( ET+TT ) endocrine therapy ( ET ) per approve Health Canada indication per available expand treatment protocol ( ) compassionate access program either 1st , 2nd 3rd line advance metastatic setting . Date initiation treatment maximum one month prior date enrollment study . 1st , 2nd 3rd line therapy advance setting define first , second third treatment respectively metastatic setting ( could include endocrine monotherapy , target therapy combination endocrine therapy chemotherapy ) . 7 . The decision use ET ET+TT reach prior independently current study . EXCLUSION CRITERIA : 1 . Patient receive chemotherapy baseline/study entry exclude ( however patient could receive one line chemotherapy metastatic setting prior study entry subsequent therapy completion ET ET+TT treatment ) . 2 . Patient receive 3 line systemic therapy metastatic setting . 3 . Patient participate clinical trial investigational treatment exception expand treatment protocol access program . 4 . Patient undergoing treatment consider standard care per regional policy guideline exception treatment access via expand treatment protocol access program . This include offlabel use medication .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HR+ HER2</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>advanced breast cancer</keyword>
	<keyword>non steroidal aromatase inhibitor ( NSAI ) exposure</keyword>
	<keyword>metastatic</keyword>
	<keyword>endocrine therapy</keyword>
	<keyword>target therapy</keyword>
	<keyword>prospective</keyword>
	<keyword>observational</keyword>
	<keyword>registry</keyword>
	<keyword>real world set</keyword>
	<keyword>non-interventional</keyword>
	<keyword>Canadian</keyword>
</DOC>